Laura Waite

Laura Waite

Auto-generated profile, based on publicly available information

Laura Waite

South Eastern Melbourne Primary Health Network Australia, Victorian Department of Health, Melbourne, Victoria, Australia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2024 in Journal of Global Health
Verified
Journal Article
Open access
ACAlexander Chen
Alexander Chen
AMAna Olga Mocumbi
Ana Olga Mocumbi
DODike B. Ojji
Dike B. Ojji
LWLaura Waite
Laura Waite
YCYih-Kai Chan
Yih-Kai Chan
SSSimon Stewart
Simon Stewart
Background There is minimal data on the number of adolescents in sub-Saharan Africa (SSA) with elevated blood pressure (BP) at increased risk of future cardiovascular events. Combining country -specific population data with data derived from two previously conducted meta -analyses (one African -specific, one based on international cohorts), we sought to address this knowledge deficit. Methods We used meta -analysis data from 37 926 adolescents participating in 36 contemporary SSA studies to generate sex -specific proportions of adolescents aged 10-14 and 15-19 years with elevated BP. The estimates were applied to the 2021 World Bank population data for each country in SSA. We then applied the rate of cardiovascular events attributable to elevated BP levels, derived from a meta -analysis of 17 observational, longitudinal cohort studies comprising 4.5 million young adults (non -African), to determine the excess number of cardiovascular events linked to hypertension among those aged 15-19 years transitioning to adulthood. Results The estimated prevalence of elevated BP among male and female adolescents aged 10-14 years living in SSA was 7.2% (95% confidence interval (CI) = 4.9-9.9) and 6.9% (95% CI = 4.7-9.5), respectively, which increased to 13.0% (95% CI = 10.6-15.6) and 12.5% (95% CI = 10.4-15.3) among male and female adolescents aged 15-19 years, respectively. Consequently, we estimate that 13.6/138.0 million (95% CI = 10.4-17.3) male and 12.9/135.7 million (95% CI = 9.83-16.3) female adolescents living in SSA have elevated BP. Among the estimated 16.1 million adolescents aged 15-19 years with elevated BP approaching adulthood, the projected excess in cardiovascular events attributable to hypertension (vs normotension) is 201 000 (95% CI = 115 000-322 000) to 503 000 (95% CI = 286 000-805 000) over the next 10-25 years. Conclusions Based on the best available data, we estimate that 26.5 million adolescents living in SSA have elevated BP. If left undetected and untreated among those approaching adulthood (those aged 15-19 years), they will experience >0.5 million excess cardiovascular events associated with persistently elevated BP within the next 25 years.

26 March 2018 in Annals of Pharmacotherapy
Verified
Journal Article
Closed access
RDRyan G. D’ANgelo
Ryan G. D’ANgelo
TMThaddeus McGiness
Thaddeus McGiness
LWLaura H. Waite
Laura H. Waite
Objective: To synthesize the literature and provide guidance to practitioners regarding double therapy (DT) and triple therapy (TT) in patients with atrial fibrillation (AF) requiring percutaneous coronary intervention (PCI). Data Sources: PubMed and MEDLINE (January 2000 to February 2018) were searched using the following terms: atrial fibrillation, myocardial infarction, acute coronary syndrome, percutaneous coronary intervention, anticoagulation, dual-antiplatelet therapy, clopidogrel, aspirin, ticagrelor, prasugrel, and triple therapy. Study Selection and Data Extraction: The results included randomized and nonrandomized clinical trials and meta-analyses. Each study was reported based on study design, population, intervention, comparator, and key cardiovascular (CV) and bleeding outcomes. Data Synthesis: A total of 15 studies were included in the review. The majority of studies evaluating DT and TT utilized clopidogrel and warfarin as components of the regimen, although there are emerging data with newer agents. Evidence purporting DT regimens to be equally effective in preventing CV events and improved safety profiles compared with TT regimens included populations with relatively low risk for recurrent CV events, and many of these studies were observational in nature. Overall, current evidence as well as American and European guidelines support the use of TT in patients with AF who require PCI for the least possible amount of time, depending on patient-specific factors involving bleeding and thrombosis. Conclusions: In the majority of patients with AF who require PCI, TT should be used for the shortest period of time possible. DT regimens may be used in patients requiring PCI who have low risk for thrombosis and/or high bleeding risk.

14 November 2023 in INNOVATIONS in pharmacy
Verified
Journal Article
Open access
PDF file
SOSong Oh
Song Oh
BCBrooklyn Cobb
Brooklyn Cobb
JHJames Hollands
James Hollands
HKHaley Kavelak
Haley Kavelak
LWLaura Waite
Laura Waite
ABAngela Bingham
Angela Bingham
Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, and review articles that focus on the leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy is an academic, peer reviewed, open-access journal. Sponsored by U of MN College of Pharmacy Inspiring Inquiry and Improvement in Pharmacy Practice, Education, and Policy. A quarterly publication featuring case studies, clinical experiences, commentaries, idea papers, original research, review articles, and student projects that focus on leading edge, novel ideas for improving, modernizing, and advancing pharmacy practice, education, and policy. INNOVATIONS in pharmacy.